NASDAQ:NYMX - Nymox Pharmaceutical Stock Price, Forecast & News

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Nymox Pharmaceutical Corp (NASDAQ:NYMX) announced its quarterly earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.08 million during the quarter. Nymox Pharmaceutical had a negative return on equity of 174.16% and a negative net margin of 12,217.59%. View Nymox Pharmaceutical's Earnings History.

Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Nymox Pharmaceutical.

News coverage about NYMX stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nymox Pharmaceutical earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Nymox Pharmaceutical.

Nymox Pharmaceutical saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,830,000 shares, an increase of 23.6% from the January 15th total of 1,480,000 shares. Based on an average trading volume of 124,500 shares, the short-interest ratio is currently 14.7 days. Currently, 4.6% of the company's shares are short sold. View Nymox Pharmaceutical's Current Options Chain.

Some companies that are related to Nymox Pharmaceutical include Heska (HSKA), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), GeneNews (GNWSF), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV) and Akers Biosciences (AKER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), NovaBay Pharmaceuticals (NBY), Biocept (BIOC), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), Rigel Pharmaceuticals (RIGL), MEI Pharma (MEIP) and Amarin (AMRN).

Nymox Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of America Corp DE (0.16%), Wedbush Securities Inc. (0.06%), Goldman Sachs Group Inc. (0.06%), Patriot Financial Group Insurance Agency LLC (0.05%), Renaissance Technologies LLC (0.05%) and Credit Suisse AG (0.05%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham. View Institutional Ownership Trends for Nymox Pharmaceutical.

NYMX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Bank of America Corp DE and Willow Creek Wealth Management Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

NYMX stock was bought by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC, Credit Suisse AG, Virtu Financial LLC, Renaissance Technologies LLC, Tower Research Capital LLC TRC and Goldman Sachs Group Inc.. Company insiders that have bought Nymox Pharmaceutical stock in the last two years include Erik Danielsen, James George Robinson and Randall J Lanham. View Insider Buying and Selling for Nymox Pharmaceutical.

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NYMX stock can currently be purchased for approximately $3.00.

Nymox Pharmaceutical has a market capitalization of $209.56 million and generates $300,000.00 in revenue each year. View Additional Information About Nymox Pharmaceutical.

The official website for Nymox Pharmaceutical is http://www.nymox.com/.

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]